You are here: Home / Publications / Multianalyte profiling of serum cytokines for detection of pancreatic cancer.

Multianalyte profiling of serum cytokines for detection of pancreatic cancer.

  • Zeh HJ
  • Winikoff S
  • Landsittel DP
  • Gorelik E
  • Marrangoni AM
  • Velikokhatnaya L
  • Winans MT
  • Lee K
  • Moser A
  • Bartlett D
  • Lotze MT
  • Siegfried JM
  • Whitcomb D
  • Papacristou G
  • Slivka A
  • Bigbee WL
  • Lokshin AE

17192050

Cancer Biomark. 2005 1 (6).

Early detection of pancreatic cancer might improve clinical outcome. Significant alterations in the levels of individual serum cytokines have been reported in pancreatic cancer. We hypothesized that a multicytokine panel could serve as biomarkers for pancreatic cancer. To evaluate the diagnostic utility of such a panel, we have utilized a novel multianalyte LabMAP profiling technology that allows simultaneous measurement of multiple markers. In this study, a panel of 31 serological markers including cytokines, chemokines, growth and angiogenic factors in combination with CA 19-9 was analyzed in sera of pancreatic cancer patients, patients with chronic pancreatitis, and matched control healthy subjects. Statistical analysis identified a multicytokine panel that was able to distinguish pancreatic cancer from healthy controls with a sensitivity of 85.7% and specificity of 92.3%, which was superior to performance of CA 19-9 alone. Importantly, a multicytokine panel allowed the discrimination of pancreatic cancer from chronic pancreatitis with high sensitivity of 98% and specificity of 96.4%. In conclusion, we demonstrated that analysis of multiple serum cytokines using a novel LabMAP technology is a promising approach for development of a diagnostic assay for pancreatic cancer.

This icon signifies that something is happening and we kindly ask you to please wait